

CONTENTS

1. Introduction	1-18
1.1 Drug design	1
1.1.1 Ligand based drug design	2
1.1.1.1 QSAR	2
1.1.1.2 Pharmacophore modeling	2
1.1.1.3 Virtual screening	3
1.1.2 Structure based drug design	3
1.1.2.1 Docking	3
1.1.2.2 <i>De novo</i> design	3
1.1.2.3 Virtual screening	4
1.2 Obesity	4
1.3 Different approaches for the treatment of obesity	5
1.3.1. Lifestyle intervention	6
1.3.2 Pharmacotherapy	6
1.3.3 Bariatric surgery	9
1.4 Endocannabinoids	10
1.5 Cannabinoid receptors	11
1.6 Signal transduction mechanisms in CB1 receptors	12
1.7 Role of CB1 receptors in obesity	13
1.8 Selectivity issues	15
1.9 Some centrally and peripherally acting CB1 receptor antagonists	17
2. Review of literature	19-61
2.1 Vicinal diaryl substituted heterocyclic compounds	19
2.1.1 Five membered heterocycles	20
2.1.1.1 Thiophene derivatives	20
2.1.1.2 Pyrrole derivatives	20
2.1.1.3 Pyrazole derivatives	22
2.1.1.4 Imidazole derivatives	38
2.1.1.5 Triazole derivatives	40
2.1.1.6 Pyrrolidine derivatives	41
2.1.1.7 Pyrazoline derivatives	42
2.1.1.8 Imidazoline derivatives	45
2.1.2 Six membered heterocycles	45
2.1.2.1 Pyridine derivatives	45
2.1.2.2 Pyrazine derivatives	46
2.1.2.3 1,4,5,6-Tetrahydropyridazine derivatives	47
2.1.2.4 Piperidine derivatives	47
2.1.2.5 Morpholine derivatives	48
2.1.3 Fused diaryl heterocycles	48
2.1.3.1 Purine derivatives	48
2.1.3.2 Fused pyridine ring derivatives	49
2.1.3.3 Fused pyrimidine derivatives	51
2.2 Non-vicinal diaryl containing compounds	53
2.2.1 Acyclic derivatives	53
2.2.2 (Thio)hydantoin derivatives	54
2.2.3 Benzodioxole derivatives	54
2.2.4 Benzhydrylpiperazine derivatives	55
2.2.5 Benzhydryl derivatives	55

2.3 Miscellaneous compounds	55
2.3.1 Indole derivatives	55
2.3.2 Benzofuran derivatives	56
2.3.3 Coumarin derivatives	57
2.3.4 Dibenzothiazepine derivatives	57
2.3.5 Pyrrolo[1,2- <i>a</i>]quinoxaline derivatives	58
2.4 Molecular modeling studies	58
3. Aims and objectives	62-63
4. Results and discussion	64-139
4.1 Determining structural requirements for the peripherally acting 1,5-diaryl pyrazole containing CB1 receptor antagonists as anti-obesity agents by 3D-QSAR (CoMFA/CoMSIA) studies. Designing of some newer compounds having better activity and properties	64
4.1.1 Dataset	65
4.1.2 Distribution of training and test set	65
4.1.3 Alignment rules	65
4.1.3.1 Atom-based alignment	66
4.1.3.2 Centroid-based alignment	66
4.1.3.3 Centroid and atom-based alignment	67
4.1.3.4 Data-based alignment	67
4.1.4 CoMFA analysis	72
4.1.5 CoMSIA analysis	74
4.1.6 Validation of the best CoMSIA model	75
4.1.6.1 Internal validation	76
4.1.6.2 Fischer statistics (F-test)	76
4.1.6.3 Y-Randomization test	76
4.1.6.4 Bootstrapping	77
4.1.6.5 External Validation	77
4.1.6.6 Modified r^2 (r_m^2)	77
4.1.6.7 Tropsha's validation tests	78
4.1.6.8 Applicability domain (APD)	79
4.1.6.9 Validation of the best model using external compounds reported in the literature	80
4.1.7 Graphical interpretation of the contour maps	82
4.1.8 Designing of novel CB1 receptor antagonists using the best developed CoMSIA model (SHA)	86
4.2 Development of pharmacophore models and 3D-QSAR (atom-based) models using different scaffolds for the identification of the essential features responsible for CB1 receptor antagonistic activity	91
4.2.1 Selection of dataset for pharmacophore and 3D-QSAR (atom-based) model	91
4.2.2 Pharmacophore modeling	94
4.2.3 Analysis of 3D-QSAR (atom-based) model	96
4.2.3.1 Validation of the best developed 3D-QSAR model (AHRR.6)	98
4.2.3.1.1 Validation by statistically parameters	98
4.2.3.1.2 Additional validation of the model using external data set	100
4.2.3.1.3 Applicability domain (APD)	101
4.2.3.2 Graphical interpretation of the developed 3D-QSAR (atom-based) model	101
4.2.3.2.1 Effect of substitution of bulky groups	102

4.2.3.2.2	Effect of electron withdrawing groups	104
4.2.3.2.3	Analysis of H-bond donor effects	106
4.2.3.2.4	Effect of hydrophobic groups	108
4.3	Performing of virtual screening for the identification of novel scaffolds by using different filters like pharmacophore model, 3D-QSAR (atom-based), molecular docking, Lipinski's rule of five, CNS score and receptor-ligand interactions	110
4.3.1	First Filter: Pharmacophore features	110
4.3.2	Second Filter: Molecular docking	110
4.3.3	Third Filter: Lipinski's rule of five	112
4.3.4	Fourth filter: Application of 3D-QSAR (atom-based) model to predict the activity	112
4.3.5	Fifth Filter: CNS score and receptor interactions	112
4.4	Hit optimization through molecular modeling techniques and synthesis of the designed compounds	116
4.4.1	Identification of hit (V11) as anti-obesity agent	116
4.4.2	Optimization of the hit V11 (1)	118
4.4.3	Chemistry	122
4.4.3.1	Synthesis of 5-substituted 4-amino-2-mercaptopyrimidine derivatives (5 and 6)	124
4.4.3.2	Synthesis of 2-substituted 2-chloro-1-(10 <i>H</i> -phenothiazin-10-yl)ethanone derivatives (12-15)	124
4.4.3.3	Synthesis of 1-(2-substituted-10 <i>H</i> -phenothiazin-10-yl)-2-substituted-2-ylthio)ethanones (1 , 18-32)	124
4.4.3.4	Synthesis of 10-(3-chloropropyl)-10 <i>H</i> -phenothiazine derivatives (34-37)	130
4.4.3.5	Synthesis of 5-substituted 2-(3-(2-substituted-10 <i>H</i> -phenothiazin-10-yl)propylthio)-4-aminopyrimidine compounds (38-45)	131
4.5	Pharmacological evaluation/screening of the synthesized compounds as peripherally acting CB1 receptor antagonists for the treatment of obesity	134
4.5.1	<i>In vitro</i> permeability assay of the test compounds	134
4.5.2	Acute hypophagic effect of the test compounds	135
4.6	Molecular modeling and SAR of the synthesized compounds	136
4.6.1	Pharmacophore mapping	136
4.6.2	Docking studies	137
4.6.3	Structure Activity Relationship (SAR)	138
5.	Experimental	140-170
5.1	Molecular modeling studies	140
5.1.1	Hardwares and softwares used in the molecular modeling	140
5.1.1.1	Hardwares	140
5.1.1.2	Softwares	140
5.1.2	Dataset, and selection of training and test set	141
5.1.3	Conversion of biological activities in terms of pIC_{50}/pK_i (Negative logarithm of IC_{50}/K_i in molar concentrations)	141
5.1.4	3D-QSAR (CoMFA and CoMSIA) studies	141
5.1.4.1	Chemical structure building and energy minimization of the structures	141
5.1.4.2	Molecular alignment	142
5.1.4.2.1	Atom-based alignment	142
5.1.4.2.2	Centroid-based alignment	142

5.1.4.2.3 Centroid and atom-based alignment	143
5.1.4.2.4 Data-based alignment	143
5.1.4.3 CoMFA and CoMSIA interaction energy calculations	143
5.1.4.4 Partial least square (PLS) analysis	143
5.1.4.5 Predictive accuracy of CoMFA and CoMSIA models	144
5.1.4.6 Validation parameters	144
5.1.5 Development of pharmacophore and 3D-QSAR (atom-based) models using PHASE module	146
5.1.5.1 Development of pharmacophore model	146
5.1.5.2 Development of 3D-QSAR (atom-based) model in PHASE module	147
5.1.6 Virtual screening	148
5.1.6.1 Using pharmacophore model - the first filter	148
5.1.6.2 Docking of the resulting compounds - the second filter	149
5.1.6.2.1 Structure of CB1 receptor	149
5.1.6.2.2 Protein preparation and receptor grid generation	149
5.1.6.2.3 Docking of the ligands into the receptor grid	150
5.1.6.3 Applying Lipinski's rule of five - the third filter	150
5.1.6.4 Predicting the activity by 3D-QSAR (atom-based) model - the fourth filter	151
5.1.6.5 Other filters	151
5.2 Chemical work	151
5.2.1 4-Amino-2-mercaptopyrimidine-5-carbonitrile (5)	151
5.2.2 Ethyl 4-amino-2-mercaptopyrimidine-5-carboxylate (6)	152
5.2.3 2-Chloro-1-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)ethanone (12)	152
5.2.4 2-Chloro-1-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)ethanone (13)	153
5.2.5 2-Chloro-1-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)ethanone (14)	153
5.2.6 2-Chloro-1-(10 <i>H</i> -phenothiazin-10-yl)ethanone (15)	153
5.2.7 4-Amino-2-(2-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethyl-thio)pyrimidine-5-carbonitrile (1)	153
5.2.8 4-Amino-2-(2-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethylthio)pyrimidine-5-carbonitrile (18)	154
5.2.9 4-Amino-2-(2-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethylthio)pyrimidine-5-carbonitrile (19)	155
5.2.10 4-Amino-2-(2-oxo-2-(10 <i>H</i> -phenothiazin-10-yl)ethylthio)pyrimidine-5-carbonitrile (20)	155
5.2.11 Ethyl 4-amino-2-(2-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethylthio)pyrimidine-5-carboxylate (21)	156
5.2.12 Ethyl 4-amino-2-(2-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethylthio)pyrimidine-5-carboxylate (22)	156
5.2.13 Ethyl 4-amino-2-(2-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)-2-oxoethylthio)pyrimidine-5-carboxylate (23)	157
5.2.14 Ethyl 4-amino-2-(2-oxo-2-(10 <i>H</i> -phenothiazin-10-yl)ethylthio)pyrimidine-5-carboxylate (24)	158
5.2.15 2-(5-(4-Pyridyl)-1,3,4-oxadiazol-2-ylthio)-1-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)ethanone (25)	158
5.2.16 1-(2-Chloro-10 <i>H</i> -phenothiazin-10-yl)-2-(5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio)ethanone (26)	159
5.2.17 1-(2-Methoxy-10 <i>H</i> -phenothiazin-10-yl)-2-(5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio)ethanone (27)	159
5.2.18 1-(10 <i>H</i> -Phenothiazin-10-yl)-2-(5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio)ethanone (28)	160
5.2.19 2-(4-Amino-5-(4-pyridyl)-4 <i>H</i> -1,2,4-triazol-3-ylthio)-1-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)ethanone (29)	160

5.2.20 2-(4-Amino-5-(4-pyridyl)-4 <i>H</i> -1,2,4-triazol-3-ylthio)-1-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)ethanone (30)	161
5.2.21 2-(4-Amino-5-(4-pyridyl)-4 <i>H</i> -1,2,4-triazol-3-ylthio)-1-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)ethanone (31)	161
5.2.22 2-(4-Amino-5-(4-pyridyl)-4 <i>H</i> -1,2,4-triazol-3-ylthio)-1-(10 <i>H</i> -phenothiazin-10-yl)ethanone (32)	162
5.2.23 10-(3-Chloropropyl)-2-trifluoromethyl-10 <i>H</i> -phenothiazine (34)	162
5.2.24 2-Chloro-10-(3-chloropropyl)-10 <i>H</i> -phenothiazine (35)	163
5.2.25 10-(3-Chloropropyl)-2-methoxy-10 <i>H</i> -phenothiazine (36)	163
5.2.26 10-(3-Chloropropyl)-10 <i>H</i> -phenothiazine (37)	163
5.2.27 4-Amino-2-(3-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carbonitrile (38)	164
5.2.28 4-Amino-2-(3-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carbonitrile (39)	164
5.2.29 4-Amino-2-(3-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carbonitrile (40)	165
5.2.30 4-Amino-2-(3-(10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carbonitrile (41)	165
5.2.31 Ethyl 4-amino-2-(3-(2-trifluoromethyl-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carboxylate (42)	166
5.2.32 Ethyl 4-amino-2-(3-(2-chloro-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carboxylate (43)	167
5.2.33 Ethyl 4-amino-2-(3-(2-methoxy-10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carboxylate (44)	167
5.2.34 Ethyl 4-amino-2-(3-(10 <i>H</i> -phenothiazin-10-yl)propylthio)pyrimidine-5-carboxylate (45)	168
5.3 Biological work	168
5.3.1 <i>In vitro</i> blood-brain permeability assay	168
5.3.2 Evaluation of hypophagic response of the test compounds	169
6. Conclusion	171-173
7. References	174-192
Publications and presentations	
Supplementary material	